Table 1.
Covariate | Estimate | Stand Error | Hazard Ratio | HR 95% CI | p |
---|---|---|---|---|---|
Histology: Adenocarcinoma vs Squamous | −0.187 | 0.285 | 0.830 | 0.474–1.452 | 0.513 |
Gender: Male vs Female | 0.153 | 0.277 | 1.165 | 0.676–2.007 | 0.582 |
Age | 0.026 | 0.014 | 1.027 | 0.999–1.055 | 0.062 |
Race: Caucasian vs others | 0.544 | 0.721 | 1.723 | 0.419–7.086 | 0.451 |
Smoking: Ever vs Never | 0.653 | 0.471 | 1.922 | 0.764–4.834 | 0.165 |
Smoking: Current vs Never | 0.637 | 0.496 | 1.890 | 0.716–4.993 | 0.199 |
Former vs Never | 0.668 | 0.490 | 1.951 | 0.746–5.098 | 0.173 |
Nodes: N1 vs N0 | 1.096 | 0.302 | 2.991 | 1.655–5.406 | 0.0003 |
No. nodes positive | 0.383 | 0.106 | 1.467 | 1.191–1.808 | 0.0003 |
Tumor diameter (cm) | 0.123 | 0.058 | 1.131 | 1.009–1.267 | 0.035 |
Pathologic Stage: II vs I | 0.945 | 0.302 | 2.573 | 1.425–4.647 | 0.002 |
CAIX, membrane* | 0.002 | 0.001 | 1.002 | 0.999–1.004 | 0.244 |
CAIX, cytoplasm* | 0.002 | 0.002 | 1.002 | 0.999–1.005 | 0.249 |
COX2, cytoplasm* | 0.001 | 0.001 | 1.001 | 0.998–1.004 | 0.502 |
CTR1, cytoplasm* | 0.001 | 0.002 | 1.001 | 0.998–1.005 | 0.436 |
CTR1, nuclear* | 0.000 | 0.002 | 1.000 | 0.997–1.004 | 0.873 |
DNMT1, cytoplasm* | −0.002 | 0.002 | 0.998 | 0.993–1.002 | 0.256 |
DNMT1, nuclear* | 0.004 | 0.004 | 1.004 | 0.996–1.012 | 0.352 |
DcR2, cytoplasm* | 0.004 | 0.002 | 1.004 | 0.999–1.008 | 0.134 |
ERCC1, cytoplasm* | −0.002 | 0.002 | 0.998 | 0.993–1.002 | 0.343 |
ERCC1, nuclear* | −0.001 | 0.002 | 0.999 | 0.995–1.002 | 0.558 |
HIF1α, cytoplasm* | 0.001 | 0.002 | 1.001 | 0.998–1.004 | 0.544 |
HIF1α, nuclear* | 0.007 | 0.006 | 1.007 | 0.995–1.019 | 0.245 |
Rb, cytoplasm* | −0.003 | 0.002 | 0.997 | 0.993–1.002 | 0.224 |
Rb, nuclear* | 0.001 | 0.002 | 1.001 | 0.997–1.004 | 0.738 |
SHARP2, cytoplasm* | −0.003 | 0.003 | 0.997 | 0.992–1.002 | 0.219 |
SHARP2, nuclear* | 0.002 | 0.002 | 1.002 | 0.999–1.005 | 0.262 |
SURVIVIN, cytoplasm* | 0.002 | 0.002 | 1.002 | 0.998–1.005 | 0.426 |
SURVIVIN, nuclear* | 0.002 | 0.001 | 1.002 | 0.999–1.005 | 0.24 |
TGFβ, membrane* | −0.004 | 0.003 | 0.996 | 0.991–1.002 | 0.16 |
TGFβ, cytoplasm* | −0.004 | 0.002 | 0.996 | 0.991–1.000 | 0.065 |
VEGF, cytoplasm* | −0.002 | 0.002 | 0.998 | 0.994–1.003 | 0.434 |
VEGF, nuclear* | 0.005 | 0.008 | 1.005 | 0.989–1.021 | 0.556 |
p14ARF, cytoplasm* | −0.003 | 0.004 | 0.997 | 0.990–1.004 | 0.431 |
p14ARF, nuclear* | 0.005 | 0.006 | 1.005 | 0.994–1.016 | 0.385 |
p16INK4, cytoplasm* | −0.002 | 0.001 | 0.998 | 0.996–1.001 | 0.268 |
p16INK4, nuclear* | −0.001 | 0.001 | 0.999 | 0.997–1.002 | 0.513 |
phospho Rb, cytoplasm* | 0.000 | 0.004 | 1.000 | 0.991–1.008 | 0.923 |
phospho Rb, nuclear* | 0.001 | 0.002 | 1.001 | 0.996–1.005 | 0.751 |
p21WAF1/CIP1, nuclear* | 0.003 | 0.002 | 1.003 | 0.999–1.008 | 0.109 |
p53, nuclear* | −0.001 | 0.001 | 0.999 | 0.997–1.002 | 0.491 |
Ki67, nuclear* | 0.002 | 0.002 | 1.002 | 0.998–1.005 | 0.377 |
CAIX, membrane, >0 vs 0 | 0.776 | 0.323 | 2.172 | 1.154–4.090 | 0.016 |
CAIX, cytoplasm, >0 vs 0 | 0.520 | 0.521 | 1.681 | 0.605–4.672 | 0.319 |
COX2, cytoplasm, >0 vs 0 | 0.192 | 0.474 | 1.212 | 0.478–3.072 | 0.685 |
CTR1, nuclear, >0 vs 0 | 0.091 | 0.313 | 1.095 | 0.593–2.022 | 0.772 |
DNMT1, cytoplasm, >0 vs 0 | −0.200 | 0.310 | 0.818 | 0.446–1.503 | 0.518 |
DNMT1, nuclear, >0 vs 0 | 0.480 | 0.311 | 1.617 | 0.880–2.972 | 0.122 |
DcR2, cytoplasm, >0 vs 0 | 0.393 | 0.598 | 1.482 | 0.459–4.788 | 0.511 |
ERCC1, cytoplasm, >0 vs 0 | −0.274 | 0.291 | 0.760 | 0.430–1.345 | 0.346 |
ERCC1, nuclear, >0 vs 0 | −0.367 | 0.289 | 0.693 | 0.393–1.221 | 0.204 |
HIF1α, cytoplasm, >0 vs 0 | −0.160 | 0.521 | 0.852 | 0.307–2.366 | 0.759 |
HIF1α, nuclear, >0 vs 0 | 0.036 | 0.341 | 1.037 | 0.532–2.021 | 0.916 |
Rb, cytoplasm, >0 vs 0 | 0.468 | 1.011 | 1.597 | 0.220–11.58 | 0.643 |
Rb, nuclear, >0 vs 0 | 0.343 | 0.368 | 1.409 | 0.686–2.896 | 0.351 |
SHARP2, cytoplasm, >0 vs 0 | 0.216 | 0.723 | 1.241 | 0.301–5.123 | 0.766 |
SHARP2, nuclear, >0 vs 0 | −0.190 | 0.524 | 0.827 | 0.296–2.311 | 0.717 |
SURVIVIN, nuclear, >0 vs 0 | −0.194 | 0.722 | 0.824 | 0.200–3.391 | 0.789 |
TGFβ, membrane, >0 vs 0 | 0.198 | 0.285 | 1.219 | 0.697–2.130 | 0.488 |
TGFβ, cytoplasm, >0 vs 0 | −0.038 | 0.316 | 0.963 | 0.519–1.788 | 0.905 |
VEGF, nuclear, >0 vs 0 | 0.138 | 0.357 | 1.148 | 0.571–2.309 | 0.699 |
p14ARF, cytoplasm, >0 vs 0 | −0.157 | 0.308 | 0.854 | 0.468–1.561 | 0.609 |
p14ARF, nuclear, >0 vs 0 | −0.133 | 0.595 | 0.875 | 0.273–2.811 | 0.823 |
p16INK4, cytoplasm, >0 vs 0 | −0.342 | 0.286 | 0.711 | 0.405–1.246 | 0.233 |
p16INK4, nuclear, >0 vs 0 | −0.335 | 0.287 | 0.715 | 0.408–1.254 | 0.242 |
phospho Rb, cytoplasm, >0 vs 0 | 0.295 | 0.318 | 1.343 | 0.720–2.505 | 0.354 |
phospho Rb, nuclear, >0 vs 0 | 0.002 | 0.338 | 1.002 | 0.517–1.941 | 0.996 |
p21WAF1/CIP1, nuclear, >0 vs 0 | −0.103 | 0.474 | 0.902 | 0.356–2.286 | 0.829 |
p53, nuclear, >0 vs 0 | −0.076 | 0.281 | 0.927 | 0.535–1.607 | 0.787 |
Ki67, nuclear, >0 vs 0 | −0.085 | 0.522 | 0.919 | 0.331–2.555 | 0.871 |
As a continuous variable.